Review

Advances in nanotechnology-based delivery systems for curcumin

Min Sun^‡

Department of Pharmaceutics, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China

Department of Pharmacy, Central Hospital of Zibo, Zibo 255036, China

^‡These authors contributed equally to this article

Search for more papers by this author

Xun Su^‡

Department of Pharmaceutics, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China

^‡These authors contributed equally to this article

Search for more papers by this author

Buyun Ding

Department of Pharmaceutics, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China

Search for more papers by this author

Xiuli He

Department of Pharmacy, The Affiliated Hospital of Shandong Medical Institution, Jinan 250031, China

Search for more papers by this author

Xiuju Liu

Department of Pharmacy, Shandong Province Hospital, Jinan 250022, China

Search for more papers by this author

Aihua Yu

Department of Pharmaceutics, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China

Search for more papers by this author

Hongxiang Lou

Department of Natural Product Chemistry, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China

Search for more papers by this author

Guangxi Zhai

* Author for correspondence

Department of Pharmaceutics, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China.

Search for more papers by this author

Email the corresponding author at zkyjd@sdu.edu.cn

Published Online:30 Jul 2012https://doi.org/10.2217/nnm.12.80

View article

Abstract

Curcumin (CUR), a bioactive component of turmeric, which is a commonly used spice and nutritional supplement, is isolated from the rhizomes of Curcuma longa Linn. (Zingiberaceae). In recent years, the potential pharmacological actions of CUR in inflammatory disorders, cardiovascular disease, cancer, Alzheimer’s disease and neurological disorders have been shown. However, the clinical application of CUR is severely limited by its main drawbacks such as instability, low solubility, poor bioavailability and rapid metabolism. Multifarious nanotechnology-based delivery approaches have been used to enhance the oral bioavailability, biological activity or tissue-targeting ability of CUR. This article reviews potential novel drug delivery systems for CUR including liposomes, polymeric nanoparticles, solid lipid nanoparticles, micelles, nanogels, nanosuspensions, nanoemulsions, complexes and dendrimer/dimer, which provide promising results for CUR to improve its biological activities.

Keywords:

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

1 Tønnesen HH, Másson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int. J. Pharm.244(1–2),127–135 (2002).Crossref, Medline, CAS, Google Scholar
2 Wang YJ, Pan MH, Cheng AL et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharm. Biomed. Anal.15(12),1867–1876 (1997).Crossref, Medline, CAS, Google Scholar
3 Ireson CR, Jones DL, Orr S et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomarkers Prev.11(1),105–111 (2002).Medline, CAS, Google Scholar
4 Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rats. Xenobiotica8(12),761–768 (1978).Crossref, Medline, CAS, Google Scholar
5 Ravindranath V, Chandrasekhara N. In vitro studies on the intestinal absorption of curcumin in rats. Toxicology20(2–3),251–257 (1981).Crossref, Medline, CAS, Google Scholar
6 Ireson C, Orr S, Jones DJ et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res.61(3),1058–1064 (2001).Medline, CAS, Google Scholar
7 Pari L, Tewas D, Eckel J. Role of curcumin in health and disease. Arch. Physiol. Biochem.114(2),127–149 (2008).Crossref, Medline, CAS, Google Scholar
8 Anand P, Thomas SG, Kunnumakkara AB et al. Biological activities of curcumin and its analogues (congeners) made by man and mother nature. Biochem. Pharmacol.76(11),1590–1611 (2008).Crossref, Medline, CAS, Google Scholar
9 Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol. Pharm.4(6),807–818 (2007).Crossref, Medline, CAS, Google Scholar
10 Lao CD, Ruffin MT, Normolle D et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern. Med.6,10 (2006).Crossref, Medline, Google Scholar
11 Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett.269(2),199–225 (2008).▪▪ Good summary of the mechanism of curcumin (CUR) in cancer prevention.Crossref, Medline, CAS, Google Scholar
12 Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett.255,170–181 (2007).Crossref, Medline, CAS, Google Scholar
13 Collett GP, Campbell FC. Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT 116 human colon cancer cells. Carcinogenesis252,2183–2189 (2004).Crossref, Google Scholar
14 Scott DW, Loo G. Curcumin-induced GADD 153 gene up regulation in human colon cancer cells. Carcinogenesis25,2155–2164 (2004).Crossref, Medline, CAS, Google Scholar
15 Lev-Ari S, Strier L, Kazanov D et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin. Cancer Res.11,6738–6744 (2005).Crossref, Medline, CAS, Google Scholar
16 Hong JH, Ahn KS, Bae E, Jeon SS, Choi HY. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis.9,147–152 (2006).Crossref, Medline, CAS, Google Scholar
17 Kesisoglou F, Panmai S, Wu Y. Nanosizing – oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev.59(7),631–644 (2007).Crossref, Medline, CAS, Google Scholar
18 Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov. Today17(1–2),71–80 (2012).Crossref, Medline, CAS, Google Scholar
19 Immordino ML, Dosio F, Cattel L. Liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed.1(3),297–315 (2006).Link, CAS, Google Scholar
20 Webb MS, Johnstone S, Morris TJ et al.In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur. J. Pharm. Biopharm.65(3),289–299 (2007).Crossref, Medline, CAS, Google Scholar
21 Hwang TL, Lee WR, Hua SC, Fang JY. Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas. J. Dermatol. Sci.46(1),11–20 (2007).Crossref, Medline, CAS, Google Scholar
22 Xiong Y, Guo D, Wang L, Zheng X, Zhang Y, Chen J. Development of nobiliside A loaded liposomal formulation using response surface methodology. Int. J. Pharm.371(1–2),197–203 (2009).Crossref, Medline, CAS, Google Scholar
23 Zhai G, Wu J, Zhao X et al. A liposomal delivery vehicle for the anticancer agent gossypol. Anticancer Res.28(5A),2801–2805 (2008).Medline, CAS, Google Scholar
24 Sethi V, Onyuksel H, Rubinstein I. Liposomal vasoactive intestinal peptide. Methods Enzymol.391,377–395 (2005).Crossref, Medline, CAS, Google Scholar
25 Takahashi M, Uechi S, Takara K, Asikin Y, Wada K. Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. J. Agric. Food Chem.57(19),9141–9146 (2009).Crossref, Medline, CAS, Google Scholar
26 Narayanan NK, Nargi D, Randolph C, Narayanan BA. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer125(1),1–8 (2009).Crossref, Medline, CAS, Google Scholar
27 Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int. J. Oncol.32(5),1119–1123 (2008).Medline, CAS, Google Scholar
28 Wang D, Veena MS, Stevenson K et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor KB by an AKT-independent pathway. Clin. Cancer Res.14(19),6228–6236 (2008).▪ Demonstrates for the first time the mechanism of CUR inhibition in head and neck squamous cell carcinoma, that is, inhibiting NF-κB by an AKT-independent pathway.Crossref, Medline, CAS, Google Scholar
29 Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer104(6),1322–1331 (2005).Crossref, Medline, CAS, Google Scholar
30 Arbiser JL, Klauber N, Rohan R et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol. Med.4(6),376–383 (1998).Crossref, Medline, CAS, Google Scholar
31 Chen C, Johnston TD, Jeon H et al. An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein–Barr virus-transformed human B-cells. Int. J. Pharm.366(1–2),133–139 (2009).Crossref, Medline, CAS, Google Scholar
32 Sullivan CO, Birkinshaw C. In vitro degradation of insulin-loaded poly (N-butylcyanoacrylate) nanoparticles. Biomaterials25(18),4375–4382 (2004).Crossref, Medline, CAS, Google Scholar
33 Farion K, Osmond MH, Hartling L et al. Tissue adhesives for traumatic lacerations in children and adults. Cochrane Database Syst. Rev.3,CD003326 (2002).Google Scholar
34 Sun M, Gao Y, Guo CY et al. Enhancement of transport of curcumin to brain in mice by poly(N-butylcyanoacrylate) nanoparticle. J. Nanopart. Res.12(8),3111–3122 (2010).Crossref, CAS, Google Scholar
35 Mulik RS, Mönkkönen J, Juvonen RO, Mahadik KR, Paradkar AR. ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against β amyloid induced cytotoxicity using in vitro cell culture model. Mol. Pharm.7(3),815–825 (2010).Crossref, Medline, CAS, Google Scholar
36 Duan J, Zhang Y, Han S et al. Synthesis and in vitro/in vivo anticancer evaluation of curcumin-loaded chitosan/poly(butylcyanoacrylate) nanoparticles. 400(1–2),211–220 (2010).Crossref, Google Scholar
37 Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci.37(3–4),223–230 (2009).Crossref, Medline, CAS, Google Scholar
38 Anand P, Nair HB, Sung B et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem. Pharmacol.79(3),330–338 (2010).Crossref, Medline, CAS, Google Scholar
39 Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J. Ovarian Res.3,11 (2010).Crossref, Medline, Google Scholar
40 Cartiera MS, Ferreira EC, Caputo C, Egan ME, Caplan MJ, Saltzman WM. Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin. Mol. Pharm.7(1),86–93 (2009).Crossref, Google Scholar
41 Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J. Colloid Interface Sci.351(1),19–29 (2010).Crossref, Medline, CAS, Google Scholar
42 Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res.29(10),3867–3875 (2009).Medline, CAS, Google Scholar
43 Cartiera MS, Ferreira EC, Caputo C, Egan ME, Caplan MJ, Saltzman WM. Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin. Mol. Pharm.7(1),86–93 (2010).Crossref, Medline, CAS, Google Scholar
44 Nagpal K, Singh SK, Mishra DN. Chitosan nanoparticles: a promising system in novel drug delivery. Chem. Pharm. Bull.58(11),1423–1430 (2010).Crossref, Medline, CAS, Google Scholar
45 Das RK, Kasoju N, Bora U. Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine6(1),153–160 (2010).▪ The new biomaterial was adopted to prepare CUR-loaded nanoparticles to increase CUR solubility. The cytotoxicity of the nanoparticles was also evaluated.Crossref, Medline, CAS, Google Scholar
46 Akhtar F, Rizvi MM, Kar SK. Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnol. Adv.30(1),310–320 (2012).Crossref, Medline, CAS, Google Scholar
47 Kumar A, Glaum M, El-Badri N. Initial observations of cell-mediated drug delivery to the deep lung. Cell Transplant.20(5),609–618 (2011).Crossref, Medline, Google Scholar
48 Anitha A, Maya S, Deepa N et al. Efficient waters soluble O-carboxymethyl chitosan nanocarrier for the delivery of curcumin to cancer cells. Carbohydrate Polymers83(2),452–461 (2011).Crossref, CAS, Google Scholar
49 Anitha A, Maya S, Chennazhi KP, Nair SV, Tamura H, Jayakumar R. Curcumin loaded N,O-carboxymethyl chitosan nanoparticles for cancer drug delivery. J. Biomater. Sci-Polymer Edition doi:org/10.1163/092050611X581534 (2012) (Epub ahead of print).Medline, Google Scholar
50 Sanoj Rejinold N, Muthunarayanan M, Divya Rani VV et al. Curcumin loaded biocompatible thermo-responsive polymeric nanoparticles for cancer drug delivery. J. Colloid Interface Sci.360(1),39–51 (2011).Crossref, Medline, CAS, Google Scholar
51 Sanoj Rejinold N, Sreerekha PR, Chennazhi KP, Nair SV, Tamura H, Jayakumar R. Biocompatible, biodegradable and thermo-sensitive chitosan-g-poly (N-isopropylacrylamide) nanocarrier for curcumin drug delivery. Int. J. Biol. Macromol.49(2),161–172 (2011).Crossref, Medline, CAS, Google Scholar
52 Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control Release.157(2),168–182 (2012).Crossref, Medline, CAS, Google Scholar
53 Patil GV. Biopolymer albumin for diagnosis and in drug delivery. Drug Dev. Res.58,219–247 (2003).Crossref, CAS, Google Scholar
54 Kim TH, Jiang HH, Youn YS et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int. J. Pharm.403(1–2),285–291 (2011).Crossref, Medline, CAS, Google Scholar
55 Prajakta D, Ratnesh J, Chandan K et al. Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer. J. Biomed. Nanotechnol.5(5),445–455 (2009).Crossref, Medline, CAS, Google Scholar
56 Dandekar P, Dhumal R, Jain R, Tiwari D, Vanage G, Patravale V. Toxicological evaluation of pH-sensitive nanoparticles of curcumin: acute, sub-acute and genotoxicity studies. Food Chem. Toxicol.48(8–9),2073–2089 (2010).Crossref, Medline, CAS, Google Scholar
57 Shelma R, Sharma CP. Acyl modified chitosan derivatives for oral delivery of insulin and curcumin. J. Mater. Sci. Mater. Med.21,2133–2140 (2010).Crossref, Medline, CAS, Google Scholar
58 Shamji MF, Hwang P, Bullock RW, Adams SB, Nettles DL, Setton LA. Release and activity of anti-TNFα therapeutics from injectable chitosan preparations for local drug delivery. J. Biomed. Mater. Res. B. Appl. Biomater.90(1),319–326 (2009).Medline, Google Scholar
59 Kakkar V, Singh S, Singla D, Kaur IP. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol. Nutr. Food Res.54,1–9 (2010).Google Scholar
60 Mulik RS, Mönkkönen J, Juvonen RO, Mahadik KR, Paradkar AR. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int. J. Pharm.398(1–2),190–203 (2010).Crossref, Medline, CAS, Google Scholar
61 Mohanty C, Acharya S, Mohanty AK, Dilnawaz F, Sahoo SK. Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy. Nanomedicine (Lond.)5(3),433–449 (2010).Link, CAS, Google Scholar
62 Gou M, Men K, Shi H et al. Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo. Nanoscale3(4),1558–1567 (2011).Crossref, Medline, CAS, Google Scholar
63 Ma Z, Haddadi A, Molavi O, Lavasanifar A, Lai R, Samuel J. Micelles of poly(ethyleneoxide)-b-poly(ε-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. J. Biomed. Mater. Res. A.86(2),300–310 (2008).Crossref, Medline, Google Scholar
64 Song Z, Feng R, Sun M et al. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: preparation, pharmacokinetics and distribution in vivo. J. Colloid Sci.354(1),116–123 (2011).Crossref, CAS, Google Scholar
65 Raemdonck K, Demeester J, Smedt DS. Advanced nanogel engineering for drug delivery. Soft Matter5,707–715 (2009).Crossref, CAS, Google Scholar
66 Wu W, Shen J, Banerjee P, Zhou S. Water-dispersible multifunctional hybrid nanogels for combined curcumin and photothermal therapy. Biomaterials32(2),598–609 (2011).▪▪ Good example of a new application of CUR in pharmaceutical applications.Crossref, Medline, CAS, Google Scholar
67 Dandekar PP, Jain R, Patil S et al. Curcumin-loaded hydrogel nanoparticles: application in anti-malarial therapy and toxicological evaluation. J. Pharm. Sci.99(12),4992–5010 (2010).Crossref, Medline, CAS, Google Scholar
68 Mangalathillam S, Rejinold NS, Nair A, Lakshmanan VK, Nair SV, Jayakumar R. Curcumin loaded chitin nanogels for skin cancer treatment via the transdermal route. Nanoscale4(1),239–250 (2012).Crossref, Medline, CAS, Google Scholar
69 Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm.62(1),3–16 (2006).Crossref, Medline, CAS, Google Scholar
70 Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug. Deliv. Rev.47(1),3–19 (2001).Crossref, Medline, CAS, Google Scholar
71 Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol.36(1),43–48 (2008).Crossref, Medline, CAS, Google Scholar
72 Gao Y, Li Z, Sun M et al. Preparation and characterization of intravenously injectable curcumin nanosuspension. Drug Deliv.18(2),131–142 (2011).Crossref, Medline, CAS, Google Scholar
73 Gao Y, Li Z, Sun M et al. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev. Ind. Pharm.36(10),1225–1234 (2010).Crossref, Medline, CAS, Google Scholar
74 Onoue S, Takahashi H, Kawabata Y et al. Formulation design and photochemical studies of nanocrystal solid dispersion of curcumin with improved oral bioavailability. J. Pharm. Sci.99(4),1871–1881 (2010).Crossref, Medline, CAS, Google Scholar
75 Podlogar F, Gasperlin M, Tomsic M, Jamnik A, Rogac MB. Structural characterization of water-Tween40/Imwitor 308-isopropyl myristate microemulsions using different experimental methods. Int. J. Pharm.276(1–2),115–128 (2004).Crossref, Medline, CAS, Google Scholar
76 He L, Wang GL, Zhang Q. An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile. Int. J. Pharm.250(1),45–50 (2003).Crossref, Medline, CAS, Google Scholar
77 Seki J, Sonoke S, Saheki A, Fukui H, Sasaki H, Mayumi T. A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting. Int. J. Pharm.273(1–2),75–83 (2004).Crossref, Medline, CAS, Google Scholar
78 Sosnik A, Carcaboso AM, Glisoni RJ, Moretton MA, Chiappetta DA. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv. Drug. Deliv. Rev.62(4–5),547–559 (2010).Crossref, Medline, CAS, Google Scholar
79 Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm.358(1–2),285–291 (2008).Crossref, Medline, CAS, Google Scholar
80 Mou D, Chen H, Du D et al. Hydrogel-thickened nanoemulsion system for topical delivery of lipophilic drugs. Int. J. Pharm.353(1–2),270–276 (2008).Crossref, Medline, CAS, Google Scholar
81 Cui J, Yu B, Zhao Y et al. Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int. J. Pharm.371(1–2),148–155 (2009).Crossref, Medline, CAS, Google Scholar
82 Setthacheewakul S, Mahattanadul S, Phadoongsombut N, Pichayakorn W, Wiwattanapatapee R. Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. Eur. J. Pharm. Biopharm.76(3),475–485 (2010).Crossref, Medline, CAS, Google Scholar
83 Wu X, Xu J, Huang X, Wen C. Self-microemulsifying drug delivery system improves curcumin dissolution and bioavailability SMEDDS improves curcumin dissolution and bioavailability. Drug Dev. Ind. Pharm.37(1),15–23 (2011).Crossref, Medline, CAS, Google Scholar
84 Lin CC, Lin HY, Chen HC, Yu WM, Lee MH. Stability and characterization of phospholipid-based curcumin-encapsulated microemulsions. Food Chem.116(4),923–928 (2009).Crossref, CAS, Google Scholar
85 Semalty A, Semalty M, Rawat MS, Franceschi F. Supramolecular phospholipids-polyphenolics interactions: the PHYTOSOME strategy to improve the bioavailability of phytochemicals. Fitoterapia81(5),306–314 (2010).Crossref, Medline, CAS, Google Scholar
86 Cucuzza LS, Motta M, Miretti S, Accornero P, Baratta M. Curcuminoid-phospholipid complex induces apoptosis in mammary epithelial cells by STAT-3 signaling. Exp. Mol. Med.40(6),647–657 (2008).Crossref, Medline, CAS, Google Scholar
87 Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin–phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm.330(1–2),155–163 (2007).Crossref, Medline, CAS, Google Scholar
88 Liu A, Lou H, Zhao L, Fan P. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J. Pharm. Biomed. Anal.40(3),720–727 (2006).Crossref, Medline, CAS, Google Scholar
89 Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with thaof curcumin formulated with phosphatidylcholine. Cancer Chemother. Pharmacol.60(2),171–177 (2007).Crossref, Medline, CAS, Google Scholar
90 Gupta NK, Dixit VK. Bioavailability enhancement of curcumin by complexation with phosphatidyl choline. J. Pharm. Sci.100(5),1987–1995 (2011).Crossref, Medline, CAS, Google Scholar
91 Yadav VR, Suresh S, Devi K, Yadav S. Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti-inflammatory activity in rat colitis mode. AAPS Pharm. Sci. Tech.10(3),752–762 (2009).Crossref, Medline, CAS, Google Scholar
92 Yallapu MM, Jaggi M, Chauhan SC. β-cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf. B. Biointerfaces79(1),113–125 (2010).Crossref, Medline, CAS, Google Scholar
93 Yallapu MM, Jaggi M, Chauhan SC. Poly(β-cyclodextrin)/curcumin self-assembly: a novel approach to improve curcumin delivery and its therapeutic efficacy in prostate cancer cells. Macromol. Biosci.10(10),1141–1151 (2011).Crossref, Google Scholar
94 Salmaso S, Bersani S, Semenzato A, Caliceti P. New cyclodextrin bioconjugates for active tumour targeting. J. Drug Target.15(6),379–390 (2007).▪ Good example of a formulation with CUR for tumor targeting and increasing CUR solubility significantly.Crossref, Medline, CAS, Google Scholar
95 Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm.71(3),445–462 (2009).Crossref, Medline, CAS, Google Scholar
96 Shi W, Dolai S, Rizk S et al. Synthesis of monofunctional curcumin derivatives, clicked curcumin dimer, and a PAMAM dendrimer curcumin conjugate for therapeutic applications. Org. Lett.9(26),5461–5464 (2007).▪ New approach of solving CUR insolubility.Crossref, Medline, CAS, Google Scholar
97 Fung LK, Saltzman WM. Polymericimplants for cancer chemotherapy. Adv. Drug Deliv. Rev.26(2–3),209–230 (1997).Crossref, Medline, CAS, Google Scholar
98 Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev. Res.4(8),1158–1171 (2011).▪ Good summary of formulations of CUR for cancer chemoprevention.Crossref, Medline, CAS, Google Scholar
99 Wadee A, Pillay V, Choonara YE et al. Recent advances in the design of drug-loaded polymeric implants for the treatment of solid tumors. Expert Opin. Drug Deliv.8(10),1323–1340 (2011).Crossref, Medline, CAS, Google Scholar
100 Bansal SS, Vadhanam MV, Gupta RC. Development and in vitro–in vivo evaluation of polymeric implants for continuous systemic delivery of curcumin. Pharm. Res.28(5),1121–1130 (2011).Crossref, Medline, CAS, Google Scholar
101 Bansal SS, Kausar H, Vadhanam MV, Ravoori S, Gupta RC. Controlled systemic delivery by polymeric implants enhances tissue and plasma curcumin levels compared with oral administration. Eur. J. Pharm. Biopharm.80,571–577 (2012).Crossref, Medline, CAS, Google Scholar

Vol. 7, No. 7

Metrics

Downloaded 1,006 times

History

Published online 30 July 2012

Published in print July 2012

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download